Literature DB >> 29103018

Single nucleotide polymorphism rs2274084 of gap junction protein beta 2 gene among Epstein-Barr virus-associated tumors.

Hua Xiao1, Wen Liu1, Zhenzhen Zhao1, Yan Zhang1,2, Yingying Song1, Bing Luo1.   

Abstract

BACKGROUND: Gap junction protein beta 2 gene (GJB2) encodes one of connexins- Connexin 26 (Cx26), which mainly expressed in epithelial cells. Cx26 is usually considered a channel to exchange information between cells, which plays a critical role in tumor cell proliferation.
OBJECTIVE: We investigated GJB2 rs2274084 polymorphism in three types of tumors, including nasophoryngeal carcinoma (NPC), gastric cancer (GC) and lymphoma.
METHODS: Proteinase K digestion and phenolchloroform purification and QIAamp DNA FFPE tissue kit was used for DNA extraction. The genotype of GJB2 gene rs2274084 was detected through Sequenom MassARRAY SNP technique. The Chi-square test and Fisher's exact test were used to compare the differences between two groups.
RESULTS: The genotype frequency of GJB2 gene rs2274084 was significantly different between EBV-positive NPC and normal control (P< 0.05). However, for EBV-associated gastric cancer (EBVaGC), EBV-negative gastric cancer (EBVnGC) and lymphoma, no significant differences were found in comparison with the normal control.
CONCLUSIONS: The mutation rate of TT genotype was a risk factor to the occurrence of EBV-positive NPC.

Entities:  

Keywords:  Connexin 26; EBV; GJB2; NPC; SNP

Mesh:

Substances:

Year:  2018        PMID: 29103018     DOI: 10.3233/CBM-170078

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  2 in total

1.  The human ATF1 rs11169571 polymorphism associated with risk of nasopharyngeal carcinoma in Southern Chinese populations.

Authors:  Shutang Peng; Guo-Liang Huang; Nansong Xu; Yan Lu; Liuyan Zeng; Xin Li; Shengqun Luo; Xiaoming Lyu; Qiang Jiang; Tong Li; Zhiwei He
Journal:  Cancer Med       Date:  2019-03-23       Impact factor: 4.452

2.  miR-492 Promotes Cancer Progression by Targeting GJB4 and Is a Novel Biomarker for Bladder Cancer.

Authors:  Kai Wang; Hang Lü; Hongchen Qu; Qingpeng Xie; Tao Sun; Ou Gan; Bin Hu
Journal:  Onco Targets Ther       Date:  2019-12-24       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.